Bioavailability and Bioequivalence

Bioavailability can be defined as the amount of drug available at the target site after systemic circulation and Bioequivalence is the similarity of two drugs which release the active ingredients at the same rate, amount, &quality. In such a process, the new drugs are tested for their stability studies. The new formulations have to undergo the analytical process to get approved by the FDA as an effective and safe dosage form. It has to compare new drug with the standard product as a reference.

  • In vitro & In vivo drug studies
  • Related Conference of Bioavailability
  • Cationic prodrugs as dual gene reagents
  • Chemically, therapeutically and physically bioequivalent.
  • Cationic prodrugs as dual gene reagents
  • HPLC to monitor β-lactam plasma
  • Accelerated stability studies
  • Chromatography types and techniques

Related Conference of Bioavailability and Bioequivalence

May 30-31, 2024

9th Pharmaceutical Chemistry Conference

Paris, France
July 25-26, 2024

34th Annual European Pharma Congress

Frankfurt, Germany
September 11-12, 2024

9th International Conference on Future Pharma and Innovations

Amsterdam, Netherlands
September 25-26, 2024

4th World Congress on Rare Diseases & Orphan Drugs

Paris, France
October 31-01, 2024

37th World Congress on Pharmacology

Amsterdam, Netherlands
November 26-27, 2024

3rd World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland
November 26-27, 2024

3rd World Congress on Precision and Personalized Medicine

Zurich, Switzerland
November 28-29, 2024

12th International Conference on Clinical Trials

Vancouver, Canada
November 28-29, 2024

39th World Congress on Pharmacology and Therapeutics

Paris, France
November 28-29, 2024

4th International Conference on Pharmaceutical Chemistry

Bali, Indonesia
December 05-06, 2024

17th World Drug Delivery Summit

Dubai, UAE

Bioavailability and Bioequivalence Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in